July 2016 Br J Cardiol 2016;23:106–9 doi:10.5837/bjc.2016.025 Online First
Blandina Gomes, Kamen Valchanov, William Davies, Adam Brown, Peter Schofield
Introduction Papworth Hospital NHS Trust, Cambridge Spinal cord stimulation (SCS) therapy has been used for more than four decades in a variety of chronic pain conditions. The introduction of neurostimulation was a logical consequence of the ‘gate-control’ theory published in 1965.1 According to this model, the activation of large afferent nerve fibres inhibits pain input mediated by small fibres into the dorsal horn of the spinal cord. The goal of SCS is to attenuate discomfort by provoking paraesthesia in the same area. The European Society of Cardiology defines refractory angina as a chronic condition characterised by the presence of a
June 2016 Br J Cardiol 2016;23:61–4 doi:10.5837/bjc.2016.020
Deborah Tinson, Samantha Swartzman, Kate Lang, Sheena Spense, Iain Todd
Introduction Chronic refractory angina is defined as coronary insufficiency in the presence of coronary artery disease with clinically established reversible myocardial ischaemia that cannot be controlled by a combination of medical therapy, angioplasty and coronary bypass surgery (CABG).1 Symptom duration should exceed three months. It carries a small increased risk of mortality,2 a significant risk of morbidity3 and accounts for more than 1% of the UK’s total health service budget.4 Triggers for angina include behavioural factors, such as activity and stress. Common misconceptions (e.g. that angina may precipitate myocardial infarction) m
January 2006 Br J Cardiol 2006;13:47-50
Oliver Gosling, Cyrus Daneshvar, Nicholas Bellenger, Matthew Dawes
No content available
November 2003 Br J Cardiol 2003;10:446-9
Coronary Heart Disease Collaborative
No content available
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits